Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life

Pediatric Infectious Disease Journal

Volumn 27, Issue 8, 2008, Pages 724-730

  Schuster, Volker ^a   Otto, Walter ^b   Maurer, Lothar ^b   Tcherepnine, Patricia ^b   Pfletschinger, Ulrich ^b   Kindler, Klaus ^b   Soemantri, Peter ^b   Walther, Uta ^b   MacHoldt, Ute ^b   Douha, Martine ^c   Pierson, Patrice ^c   Willems, Paul ^b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b Pediatric Offices in Fulda Frankenthal Roding Stuttgart Trier Kleve Materborn   (Germany)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Immunogenicity; Measles mumps rubella varicella vaccine; Reactogenicity; Safety

Indexed keywords

CHICKENPOX MEASLES MUMPS RUBELLA VACCINE; MEASLES MUMPS RUBELLA VACCINE; PRIORIX TETRA; UNCLASSIFIED DRUG; VARICELLA ZOSTER VACCINE; CHICKENPOX VACCINE; MEASLES, MUMPS, RUBELLA, VARICELLA VACCINE; VIRUS ANTIBODY;

ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HUMAN; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; MALE; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SEROCONVERSION; SINGLE DRUG DOSE; SKIN REDNESS; SKIN SWELLING; TREATMENT OUTCOME; VACCINATION; BLOOD; CHICKENPOX; CONTROLLED STUDY; GERMANY; IMMUNIZATION; IMMUNOLOGY; MEASLES; MEASLES VIRUS; MUMPS; MUMPS VIRUS; RUBELLA; RUBELLA VIRUS; VARICELLA ZOSTER VIRUS; VIROLOGY;

ANTIBODIES, VIRAL; CHICKENPOX; CHICKENPOX VACCINE; FEMALE; GERMANY; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNIZATION SCHEDULE; INFANT; MALE; MEASLES; MEASLES VIRUS; MEASLES-MUMPS-RUBELLA VACCINE; MUMPS; MUMPS VIRUS; RUBELLA; RUBELLA VIRUS; TREATMENT OUTCOME;

EID: 50649113164     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318170bb22     Document Type: Article

References (38)

1. Bundesamt für Gesundheit. Impfplan für routinemässige Schutzimpfungen. Stand August 2001. Ordner Infektionskrank-heiten-Diagnose und Bekämpfung, Supplementum VIII: 1-6. BAG, Bern 2001.
2. Empfehlungen des Obersten Sanitätsrates 2007. Impfplan Österreich 2007. Available at: http://www.bmgfj.gv.at/cms/site/attachments/ 1/4/0/ CH0016/CMS1038913010412/impfplan-2007-aktuell.pdf. Accessed No-vember 26, 2007.
3. Institut de Veille Sanitaire. Calendrier vaccinal 2005 et autres avis du conseil supérieur d'hygiène publique de France relatifs à la vaccination. Bulletin épidémiologique hebdomadaire. 2005;29-30:142.
4. Robert Koch Institute. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: Juli 2006. Epidemiol Bull. 2006;30:235-254.
5. Centers for Disease Control and Prevention. Progress in reducing global measles deaths, 1999-2004. MMWR Morb Mortal Wkly Rep. 2006;55: 247-249.
6. Meyer PA, Seward JF, Jumaan AO, Wharton M. Varicella mortality: trends before vaccine licensure in the United States, 1970-1994. J Infect Dis. 2000;182:383-390.
7. Bonhoeffer J, Baer G, Muechleisen B. Prospective surveillance of hospitalisations associated with varicella-zoster virus infections in children and adolescents. Eur J Pediatr. 2005;164:366-370.
8. Rawson H, Crampin A, Noah N. Deaths from chickenpox in England and Wales 1995-7: analysis of routine mortality data. BMJ. 2001;323: 1091-1093.
9. Boelle PY, Hanslik T. Varicella in non-immune persons: incidence, hospitalization and mortality rates. Epidemiol Infect. 2002;129:599-606.
10. Banz K, Wagenpfeil S, Neiss A, et al. The burden of varicella in Germany: potential risks and economic impact. Eur J Health Econ. 2004;5:46-53.
11. Gil A, San-Martin M, Carrasco P, et al. Epidemiology of severe varicella-zoster virus infection in Spain. Vaccine. 2004;22:3947-3951.
12. Centers for Disease Control and Prevention. Prevention of varicella:recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1996;45(RR-11):1-36.
13. Centers for Disease Control and Prevention. Prevention of varicella. Update recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 1999;48(RR-6):1-5.
14. Australian Technical Advisory Group on Immunisation (ATAGI)/ National Health and Medical Research Council (NHMRC). The Australian Immunisation Handbook. 8th ed. Canberra: Australian Government Publishing Service; 2003.
15. National Advisory Committee on Immunization (NACI). Update onvaricella. Can Commun Dis Rep. 2004;30:1-26.
16. Robert Koch Institute. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: Juli 2004. Epidemiol Bull. 2004;30:235-250.
17. Rentier B, Gershon AA, European Working Group on Varicella. Consensus: varicella vaccination of healthy children-a challenge for Europe. Pediatr Infect Dis J. 2004;23:379-89.
18. Pinot de Moira A, Nardone A, ESEN2 group. Varicella zoster virus vaccination policies and surveillance strategies in Europe. Euro Surveill.2005;10:43-45.
19. Bernaola Iturbe E, Gimenez Sanchez F, Baca Cots M, et al. Vaccination schedule of the Spanish Association of Pediatrics: recommendations 2006. An Pediatr (Barc). 2006;64:74-77.
20. CDC's advisory committee recommends changes in varicella vaccinations. Child Health News. June 29, 2006.
21. Kuter B, Matthews H, Shinefield H, et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J. 2004;23:132-137.
22. Arvin A, Gershon A. Control of varicella. Why is a two-dose schedule necessary? Pediatr Infect Dis J. 2006;25:475-476.
23. Lopez AS, Guris D, Zimmerman L, et al. One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose? Pediatrics. 2006;117:e1070-e1077.
24. Centers for Disease Control and Prevention. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-04):1-40.
25. Knuf M, Habermehl P, Zepp F, et al. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. Pediatr Infect Dis J. 2006;25:12-18.
26. Sato H, Albrecht P, Hicks JT, Meyer BC, Ennis FA. Sensitive neutralization test for virus antibody. 1. Mumps antibody. Arch Virol. 1978; 58:301-311.
27. Dodet M, Dessy F, Parent I, Gerard P. Use of a neutralization assay as an alternative for assessing mumps immunization status. In: Program and Abstracts of the 24th Annual Meeting of the European Society for Pediatric Infectious Diseases; Basel, Switzerland; 2006. Abstract 387.
28. Mauldin J, Carbone K, Hsu H, Yolken R, Rubin S. Mumps virus-specific antibody titers from pre-vaccine era sera: comparison of the plaque reduction neutralization assay and enzyme immunoassays. J Clin Microbiol. 2005;43:4847-4851.
29. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213-226.
30. Watson B, Boardman C, Laufer D, et al. Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine. Clin Infect Dis. 1995;20:316-319.
31. Kuter BJ, Brown ML, Hartzel J, et al.; Study Group for ProQuad. Safety and immunogenicity of a combination measles, mumps, rubella and varicella vaccine (ProQuad). Hum Vaccin. 2006;2:205-214.
32. Vesikari T, Baer M, Willems P. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5-6 years. Pediatr Infect Dis J. 2007;26:153-158.
33. Kenny MT, Jackson JE, Medler EM, et al. Age-related immunity to measles, mumps and rubella in Middle American and United States children. Am J Epidemiol. 1976;103:174-180.
34. Wagenvoort JH, Harmsen M, Boutahar-Trouw BJ, Kraaijeveld CA, Winkler KC. Epidemiology of mumps in the Netherlands. J Hyg (Lond). 1980;85:313-326.
35. Gans H, Yasukawa L, Rinki M, et al. Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J Infect Dis.2001;184: 817-826.
36. Nolan T, McIntyre P, Roberton D, Descamps D. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubellavaricella (MMRV) vaccine. Vaccine. 2002;21:281-289.
37. Peltola H, Heinonen OP. Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins. Lancet. 1986;1:939-942.
38. Centers for Disease Control and Prevention. Measles. In: Atkinson W, Hamborsky J, McIntyre L, Wolfe S, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 10th ed. Washington, DC: Public Health Foundation; 2007:129-148.